Tracking and characterization of partial and full epithelial-mesenchymal transition cells in a mouse model of metastatic breast cancer.

Fabiana Lüönd, Natascha Santacroce, Christian Beisel, Laurent Guérard, Thomas R Bürglin, Gerhard Christofori, Nami Sugiyama

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fabiana LüöndDepartment of Biomedicine, University of Basel, 4058 Basel, Switzerland.

Natascha SantacroceDepartment of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.

Christian BeiselDepartment of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.

Laurent GuérardBiozentrum, University of Basel, 4056 Basel, Switzerland.

Thomas R BürglinDepartment of Biomedicine, University of Basel, 4058 Basel, Switzerland.

Gerhard ChristoforiDepartment of Biomedicine, University of Basel, 4058 Basel, Switzerland.

Nami SugiyamaDepartment of Biomedicine, University of Basel, 4058 Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The various stages of epithelial-mesenchymal transition (EMT) generate phenotypically heterogeneous populations of cells. Here, we detail a dual recombinase lineage tracing system using a transgenic mouse model of metastatic breast cancer to trace and characterize breast cancer cells at different EMT stages. We describe analytical steps to label cancer cells at an early partial or a late full EMT state, followed by tracking their behavior in tumor slice cultures. We then characterize their transcriptome by five-cell RNA sequencing. For complete details on the use and execution of this protocol, please refer to Luond et al. (2021).

Indexed as

Epithelial-Mesenchymal TransitionNeoplasmsAnimalsCell Line, TumorDisease Models, AnimalMiceMice, TransgenicTranscriptomeCancerCell BiologyCell DifferentiationFlow Cytometry/Mass CytometryMicroscopyMolecular BiologyRNAseqSingle Cell

Identifiers

PMID35707685

DOI10.1016/j.xpro.2022.101438

PMCPMC9189628

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.